NASDAQ:SRTS

Sensus Healthcare (SRTS) Stock Price, News & Analysis

$3.39
+0.10 (+3.04%)
(As of 04/22/2024 ET)
Today's Range
$3.16
$3.42
50-Day Range
$3.14
$4.91
52-Week Range
$1.79
$5.38
Volume
35,655 shs
Average Volume
149,464 shs
Market Capitalization
$55.56 million
P/E Ratio
113.04
Dividend Yield
N/A
Price Target
$7.50

Sensus Healthcare MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
121.2% Upside
$7.50 Price Target
Short Interest
Healthy
0.26% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Sensus Healthcare in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.90 out of 5 stars

Medical Sector

380th out of 909 stocks

Surgical & Medical Instruments Industry

45th out of 97 stocks

SRTS stock logo

About Sensus Healthcare Stock (NASDAQ:SRTS)

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, which includes applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.

SRTS Stock Price History

SRTS Stock News Headlines

The system that called 2023’s top 7 stocks is at it again…
Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.
Sensus Healthcare Inc.
A Market With a Hangover
3 Stocks to Buy That Are Up 100% or More in 2024
The system that called 2023’s top 7 stocks is at it again…
Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.
Q4 2023 Sensus Healthcare Inc Earnings Call
Earnings Preview For Sensus Healthcare
See More Headlines
Receive SRTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sensus Healthcare and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/08/2024
Today
4/22/2024
Next Earnings (Confirmed)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:SRTS
Employees
35
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.50
High Stock Price Target
$8.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+121.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$490,000.00
Pretax Margin
2.67%

Debt

Sales & Book Value

Annual Sales
$24.41 million
Cash Flow
$0.06 per share
Book Value
$2.98 per share

Miscellaneous

Free Float
14,574,000
Market Cap
$55.56 million
Optionable
Optionable
Beta
0.91
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Joseph C. SardanoMr. Joseph C. Sardano (Age 71)
    Co-Founder, Chairman & CEO
    Comp: $754.43k
  • Mr. Michael J. Sardano (Age 35)
    President, General Counsel, Corporate Secretary & Director
    Comp: $404.74k
  • Mr. Javier Rampolla (Age 51)
    Chief Financial Officer
    Comp: $439.14k
  • Ms. Magdalena Martinez (Age 34)
    Chief Operating Officer
  • Mr. Emiliano Sosa (Age 46)
    Chief Technology Officer
  • Sean Delaney
    Vice President of Regulatory Affairs & Compliance
  • Ms. Stephanie Tipton
    Vice President of Marketing
  • Dr. Mark S. Nestor
    Medical Director & Member of Medical Advisory Board
  • Dr. Clay Jefferies Cockerell (Age 67)
    Clinical Director & Member of Medical Advisory Board

SRTS Stock Analysis - Frequently Asked Questions

Should I buy or sell Sensus Healthcare stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sensus Healthcare in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SRTS shares.
View SRTS analyst ratings
or view top-rated stocks.

What is Sensus Healthcare's stock price target for 2024?

1 Wall Street analysts have issued 12-month target prices for Sensus Healthcare's shares. Their SRTS share price targets range from $7.00 to $8.00. On average, they predict the company's share price to reach $7.50 in the next year. This suggests a possible upside of 121.2% from the stock's current price.
View analysts price targets for SRTS
or view top-rated stocks among Wall Street analysts.

How have SRTS shares performed in 2024?

Sensus Healthcare's stock was trading at $2.36 on January 1st, 2024. Since then, SRTS shares have increased by 43.6% and is now trading at $3.39.
View the best growth stocks for 2024 here
.

Are investors shorting Sensus Healthcare?

Sensus Healthcare saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 33,400 shares, a decrease of 49.2% from the March 15th total of 65,800 shares. Based on an average daily volume of 162,000 shares, the short-interest ratio is currently 0.2 days. Approximately 0.3% of the company's shares are sold short.
View Sensus Healthcare's Short Interest
.

When is Sensus Healthcare's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our SRTS earnings forecast
.

How can I listen to Sensus Healthcare's earnings call?

Sensus Healthcare will be holding an earnings conference call on Thursday, May 9th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "9785929#".

How were Sensus Healthcare's earnings last quarter?

Sensus Healthcare, Inc. (NASDAQ:SRTS) released its quarterly earnings data on Thursday, February, 8th. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.12 by $0.14. The company had revenue of $12.57 million for the quarter, compared to analyst estimates of $12.10 million. Sensus Healthcare had a net margin of 1.99% and a trailing twelve-month return on equity of 1.04%.

What other stocks do shareholders of Sensus Healthcare own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sensus Healthcare investors own include Ring Energy (REI), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Nabriva Therapeutics (NBRV), Sangamo Therapeutics (SGMO), Viking Therapeutics (VKTX), Vaxart (VXRT), Amarin (AMRN), Palatin Technologies (PTN) and QUALCOMM (QCOM).

When did Sensus Healthcare IPO?

Sensus Healthcare (SRTS) raised $20 million in an IPO on Wednesday, March 30th 2016. The company issued 1,800,000 shares at $10.00-$12.00 per share. Joseph Gunnar and Feltl and Company acted as the underwriters for the IPO and Neidiger, Tucker, Bruner was co-manager.

How do I buy shares of Sensus Healthcare?

Shares of SRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SRTS) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners